B-Ingelheim pulls Japanese filing for telmisartan in diabetic nephropathy
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has withdrawn an application in Japan for the approval of Micardis (telmisartan) for the additional indication of incipient nephropathy in type 2 diabetes patients.